RMD News: Health Care Roundup: Market Talk - 1st Feb 2025, 12:44am

[annb0t]

0750 GMT – Novartis’s 2025 guidance is constructive and beats consensus expectations, Intron Health analysts say in a note. The Swiss pharma giant’s guidance is for mid-to-high single-digit sales growth, which is a 3% lift to consensus sales and EBIT, the analysts say. 0746 GMT – Novartis’s significant profit and sales beat could close the gap between its mid-term growth guidance that is clearly above market’s expectations, Vontobel analyst Stefan Schneider says in ...

>>> Read more: Health Care Roundup: Market Talk